This panel is known for screening many autoimmune disorders that affect 5-9% of the world’s population at the preclinical and clinical stages of autoimmune diseases. Unfortunately, many patients ignore initially innocuous symptoms and are only diagnosed when the disease becomes fully active, the symptoms become blatantly obvious, and the patient’s health suffers.
This indicates that autoimmune diseases are chronic, and if they are not detected at the preclinical stage, it may not be possible to heal or find a cure for the autoimmune disorder.
Anti-Nuclear Antibodies (ANA) are included in this panel because they attack normal proteins in the nucleus of the host cells. Abnormal levels of ANA serve as a biomarker for many autoimmune diseases, including:
Rheumatoid Factor (RF) is an IgM antibody that was the first autoantibody found in Rheumatoid Arthritis. It is produced by the immune system and works against our own IgG when it aggregates. Elevated RF is also detected in the blood of patients with parasitic diseases, liver disease, sarcoidosis, EBV, and SLE.
Circulating Immune Complexes (CIC) are macromolecules consisting of antibodies bound to different antigens. They play a variety of roles in the activation and regulation of phagocytes. Circulating immune complexes that bind C1q complement are present in human serum in small quantities that are removed by the liver. High levels of Immune complexes can be deposited in the joints and kidneys, contributing to inflammation and autoimmune diseases such as rheumatoid arthritis, lupus and nephropathy.
This panel is beneficial for a wide variety of patients with the following:
The Autoimmune Basic Profile assists in the detection of many systemic autoimmune diseases, including rheumatoid arthritis and mixed connective tissue disease.